Regulus Therapeutics Inc

NASDAQ:RGLS  
0.23
-0.03 (-10.61%)
Products

Regulus Therapeutics Announces Receipt Of FDA Orphan Drug Designation For Rgls8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Published: 06/21/2022 14:02 GMT
Regulus Therapeutics Inc (RGLS) - Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (adpkd).